Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment crawled date : 2021 - 09 - 30 save search
Silvercorp to Highlight Innovative Water Treatment Initiatives in Upcoming Annual Sustainability Report
Published: 2021-09-30 (Crawled : 23:00) - prnewswire.com
SVM | $3.58 0.28% 1.2M
|
Non-Energy Minerals
|
| O: 0.52%
H: 0.39%
C: -0.26%
treatment
DiaMedica Therapeutics Announces Fast Track Designation Granted to DM199 for the Treatment of Acute Ischemic Stroke
Published: 2021-09-30 (Crawled : 20:00) - biospace.com/
DMAC | $2.46 -1.21% 19K
|
Health Technology
|
| O: -0.5%
H: 6.46%
C: -0.25%
treatment stroke fast track granted fast track designation grant designation
ImmixBio Announces FDA Orphan Drug Designation for IMX-110 for the Treatment of Soft Tissue Sarcoma
Published: 2021-09-30 (Crawled : 19:00) - biospace.com/
IMMX | News | $2.205 -0.23% 59K
|
| Email alert
Add to watchlist
treatment fda orphan drug drug designation soft tissue
Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia
Published: 2021-09-30 (Crawled : 16:00) - globenewswire.com
NERV | $2.5 7.6K
|
Health Technology
|
| O: 2.82%
H: 3.3%
C: -4.4%
treatment phase 2 schizophrenia results phase 2b phase 3 roluperidone
Tactile Medical Announces Enrollment of First Patient in Randomized, Controlled Clinical Trial Evaluating the Effectiveness of Flexitouch® Plus for the Treatment of Head and Neck Lymphedema
Published: 2021-09-30 (Crawled : 16:00) - globenewswire.com
TCMD | $14.33 1.34% 63K
|
Health Technology
|
| O: 0.86%
H: 1.4%
C: 0.09%
treatment trial enroll
6 Options For Anxiety Treatment
Published: 2021-09-30 (Crawled : 15:00) - brainsway.com
BWAY | $4.84 1.04% 33K
|
Health Technology
|
| O: -0.12%
H: 0.73%
C: -1.47%
treatment
Adial Pharmaceuticals Announces Greater Than 50% of Patients Expected to Complete ONWARD™ Phase 3 Trial of AD04 for the Treatment of Alcohol Use Disorder Have Completed the Full 24-Week Treatment Period – Trial Completion Anticipated Q1 2022
Published: 2021-09-30 (Crawled : 14:00) - globenewswire.com
ADIL | $1.98 -8.76% 260K
|
Health Technology
|
| O: 0.48%
H: 3.57%
C: 2.14%
alcohol use disorder treatment phase 3 trial
TG Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Ublituximab as a Treatment for Patients with Relapsing Forms of Multiple Sclerosis
Published: 2021-09-30 (Crawled : 13:00) - biospace.com/
TGTX | News | $13.685 -2.18% 1.9M
|
Health Technology
|
| O: 0.21%
H: 3.12%
C: -1.07%
multiple sclerosis food treatment drug sclerosis license
InMed Pharmaceuticals Announces Commencement of Phase 2 Clinical Trial Investigating Cannabinol (CBN), a Rare Cannabinoid, in the Treatment of Epidermolysis Bullosa
Published: 2021-09-30 (Crawled : 13:00) - biospace.com/
INM 4 | $0.301 15K
|
Health Technology
|
| O: -2.2%
H: 1.84%
C: -1.69%
treatment phase 2 trial cannabinol rare
CNS Pharmaceuticals Doses First Group of Patients with Berubicin, an FDA-Designated Fast Track Drug Candidate, in the Potentially Pivotal Study for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2021-09-30 (Crawled : 12:15) - prnewswire.com
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.64%
H: 1.89%
C: -5.08%
CNSP | $0.204 35K
|
Health Technology
|
| O: -3.75%
H: 3.9%
C: -3.25%
berubicin treatment fda potential fast track drug designation glioblastoma
Arrowhead Pharmaceuticals Initiates Phase 2b Study of ARO-APOC3 for Treatment of Mixed Dyslipidemia
Published: 2021-09-30 (Crawled : 12:00) - biospace.com/
ARWR | $22.1 -2.26% 390K
|
Health Technology
|
| O: 1.24%
H: 3.54%
C: 1.71%
treatment phase 2 phase 2b
Gainers vs Losers
| 70% | 30% |
Top 10 Gainers
AGBA | News | $1.305 226.25% 130M
|
Finance
EGOX | $0.0503 39.72% 320M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
ZCMD | $1.905 31.38% 30M
|
Commercial Services
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
TPET | $0.4121 25.68% 45M
|
n/a
NVFY | $2.65 25.59% 33M
|
Consumer Durables
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.